Patents by Inventor Michel Journet

Michel Journet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for making reverse transcriptase inhibitors
    Patent number: 9598397
    Abstract: The present invention is directed to a novel process for synthesizing 3-(substituted phenoxy)-1-[(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl])-pyridin-2(1H)-one derivatives. The compounds synthesized by the processes of the invention are HIV reverse transcriptase inhibitors useful for inhibiting reverse transcriptase and HIV replication, and the treatment of human immunodeficiency virus infection in humans.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: March 21, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Yang Cao, Donald R. Gauthier, Jr., Guy R. Humphrey, Tetsuji Itoh, Michel Journet, Gang Qian, Benjamin D. Sherry, David M. Tschaen
  • Immobilized transaminases and process for making and using immobilized transaminase
    Patent number: 9523107
    Abstract: The invention is directed to immobilized transaminases and methods of making and using them.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: December 20, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Matthew D. Truppo, Michel Journet, Hallena Strotman, Jonathan P. McMullen, Shane T. Grosser
  • PROCESS FOR MAKING REVERSE TRANSCRIPTASE INHIBITORS
    Publication number: 20160297794
    Abstract: The present invention is directed to a novel process for synthesizing 3-(substituted phenoxy)-1-[(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl])-pyridin-2(1H)-one derivatives. The compounds synthesized by the processes of the invention are HIV reverse transcriptase inhibitors useful for inhibiting reverse transcriptase and HIV replication, and the treatment of human immunodeficiency virus infection in humans.
    Type: Application
    Filed: December 2, 2014
    Publication date: October 13, 2016
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Yang Cao, Donald R. Gauthier, Jr., Guy R. Humphrey, Tetsuji Itoh, Michel Journet, Gang Qian, Benjamin D. Sherry, David M. Tschaen
  • IMMOBILIZED TRANSAMINASES AND PROCESS FOR MAKING AND USING IMMOBILIZED TRANSAMINASE
    Publication number: 20150368682
    Abstract: The invention is directed to immobilized transaminases and methods of making and using them.
    Type: Application
    Filed: February 24, 2014
    Publication date: December 24, 2015
    Inventors: Matthew D. Truppo, Michel Journet, Hallena Strotman, Jonathan P. McMullen, Shane T. Grosser
  • Process for Making Hydroisoindoline Tachykinin Receptor Antagonists
    Publication number: 20100036135
    Abstract: The present invention is directed to a process for preparing certain hydroisoindoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The compounds are useful in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.
    Type: Application
    Filed: July 7, 2006
    Publication date: February 11, 2010
    Applicant: MERCK & CO., INC.
    Inventors: Jeffrey T. Kuethe, Jingjun Yin, Mark A. Huffman, Michel Journet
  • Process for making hydroisoindoline tachykinin receptor antagonists
    Patent number: 7544815
    Abstract: The present invention is directed to a process for preparing certain hydroisoindoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The compounds are useful in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.
    Type: Grant
    Filed: July 11, 2006
    Date of Patent: June 9, 2009
    Assignee: Merck & Co, Inc.
    Inventors: Jeffrey T. Kuethe, Jingjun Yin, Mark A. Huffman, Michel Journet
  • Process for making hydroisoindoline tachykinin receptor antagonists
    Publication number: 20070015923
    Abstract: The present invention is directed to a process for preparing certain hydroisoindoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The compounds are useful in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.
    Type: Application
    Filed: July 11, 2006
    Publication date: January 18, 2007
    Inventors: Jeffrey Kuethe, Jingjun Yin, Mark Huffman, Michel Journet
  • Process for the preparation of PGD2 antagonist
    Patent number: 6693203
    Abstract: The present invention provides an efficient process for the preparation of benzothiophenecarboxamide PGD2 antagonist, S-5751.
    Type: Grant
    Filed: June 6, 2003
    Date of Patent: February 17, 2004
    Assignee: Shionogi & Co., LTD
    Inventors: Robert Larsen, Dongwei Cai, Michel Journet, Kevin Campos
  • Process for the preparation of pgd2 antagonist
    Publication number: 20030199702
    Abstract: The present invention provides an efficient process for the preparation of benzothiophenecarboxamide PGD2 antagonist, S-5751.
    Type: Application
    Filed: June 6, 2003
    Publication date: October 23, 2003
    Inventors: Robert Larsen, Dongwei Cai, Michel Journet, Kevin Campos
  • Process for making diaryl pyridines useful as cox-2 inhibitors
    Patent number: 6369275
    Abstract: The invention encompasses a process for making compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases.
    Type: Grant
    Filed: November 17, 2000
    Date of Patent: April 9, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Ian W. Davies, Michel Journet, Linda Gerena, Robert D. Larsen, Philip J. Pye, Kai Rossen
  • Process for making diaryl pyridines useful as COX-2 inhibitors
    Patent number: 6204387
    Abstract: The invention encompasses a process for making compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases.
    Type: Grant
    Filed: March 23, 2000
    Date of Patent: March 20, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Ian W. Davies, Linda Gerena, Michel Journet, Robert D. Larsen, Philip J. Pye, Kai Rossen
  • Convergent process for the preparation of a morpholine compound
    Patent number: 6051717
    Abstract: The present invention is directed to the compound 4-N,N-dimethylaminomethyl-5-formyl-1,2,3-triazole which is a valuable intermediate in the preparation of phamaceutical compounds. The present invention is further directed to a novel convergent process for the preparation of 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)-ethoxy)-4-(5-(dimethylamino) methyl-1,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)-morpholine which is a potent and selective substance P (or neurokinin-1) receptor antagonist useful as a therapeutic agent.
    Type: Grant
    Filed: October 28, 1999
    Date of Patent: April 18, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Dongwei Cai, Michel Journet, Jason Kowal, Robert D. Larson
  • Linear process for the preparation of a morpholine compound
    Patent number: 6051707
    Abstract: The present invention is concerned with a novel linear process for the preparation of 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl) phenyl)-ethoxy)-4-(5-(dimethylamino)methyl-1,2,3-triazol-4-yl)methyl-3-(S) -(4-fluorophenyl)-morpholine which is a potent and selective substance P (or neurokinin-1) receptor antagonist usefull as a therapeutic agent.
    Type: Grant
    Filed: October 28, 1999
    Date of Patent: April 18, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Dongwei Cai, Michel Journet, Robert D. Larsen
  • Process for making diaryl pyridines useful as cox-2-inhibitors
    Patent number: 6040450
    Abstract: The invention encompasses a process for making compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases.
    Type: Grant
    Filed: September 15, 1998
    Date of Patent: March 21, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Ian W. Davies, Michel Journet, Linda Gerena, Robert D. Larsen, Philip J. Pye, Kai Rossen